Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | FLT3 Y842C |
Gene Variant Detail | |
Relevant Treatment Approaches | FLT3 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FLT3 Y842C | acute myeloid leukemia | sensitive | FLT3 Inhibitor | Midostaurin | Preclinical - Cell culture | Actionable | In a preclinical study, Rydapt (midostaurin) induced cell death and inhibited FLT3 activation and downstream STAT5 activation in primary acute myeloid leukemic blasts harboring FLT3 Y842C in culture (PMID: 15345593). | 15345593 |
FLT3 Y842C | acute myeloid leukemia | resistant | Imatinib | Preclinical | Actionable | In a preclinical study, primary AML blasts expressing FLT3 Y842C were resistant to Gleevec (imatinib) as demonstrated by constitutively phosphorylated FLT3 and STAT-5 (PMID: 15345593). | 15345593 | |
FLT3 Y842C | hematologic cancer | sensitive | FLT3 Inhibitor | Gilteritinib | Preclinical - Cell culture | Actionable | In a preclinical study, Xospata (gilteritinib) resulted in reduced cell viability in transformed cells expressing FLT3 Y842C in culture (PMID: 32040554). | 32040554 |
FLT3 Y842C | hematologic cancer | sensitive | FLT3 Inhibitor | Gilteritinib | Preclinical - Cell culture | Actionable | In a preclinical study, Xospata (gilteritinib) inhibited viability of cultured cells expressing FLT3 Y842C (PMID: 38231480). | 38231480 |
FLT3 Y842C | hematologic cancer | resistant | FLT3 Inhibitor | Quizartinib | Preclinical - Cell culture | Actionable | In a preclinical study, cultured cells expressing FLT3 Y842C were resistant to treatment with Vanflyta (quizartinib) (PMID: 38231480). | 38231480 |
FLT3 Y842C | hematologic cancer | sensitive | Foretinib | Preclinical - Cell culture | Actionable | In a preclinical study, Foretinib (GSK1363089) inhibited viability of cultured cells expressing FLT3 Y842C (PMID: 38231480). | 38231480 |